Metalloporphyrins and functional analogues as MRI contrast agents

Current Medical Imaging Reviews

Volumn 4, Issue 2, 2008, Pages 96-112

  Ni, Yicheng ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

Magnetic resonance imaging (MRI); Metalloporphyrins; Necrosis avid contrast agents (NACAs); Photodynamic therapy (PDT); Stroma; Targeting

Indexed keywords

CONGO RED; CONTRAST MEDIUM; EP 1873; EP 2104R; EVANS BLUE; GADOBENATE DIMEGLUMINE; GADOFLUORINE M; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE BISINDOLE DERIVATIVE; GADOLINIUM PENTETATE DERIVATIVE; GADOLINIUM PENTETATE METHYLPYRROPORPHYRIN MANGANESE; GADOLINIUM PENTETATE PAMOIC ACID DERIVATIVE; GADOLINIUM PENTETATE POLYGLUTAMIC ACID; GADOLINIUM TEXAPHYRIN; GADOPHRIN II; HEMATOPORPHYRIN; MESOPORPHYRIN COPPER; METALLOPORPHYRIN; MP 2269; NECROSIS AVID CONTRAST AGENT; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; P 947; PHOTOFRIN II; PORPHYRIN DERIVATIVE; TETRAKIS(4 SULFOPHENYL)PORPHINE MANGANESE; TETRAPHENYLPORPHYRIN MANGANESE; TRIPHENYLTETRAZOLIUM; TRYPAN BLUE; UNINDEXED DRUG;

ACUTE HEART INFARCTION; ATHEROSCLEROTIC PLAQUE; BLOOD CLOT; BRAIN INFARCTION; BRAIN TUMOR; CANCER DIAGNOSIS; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DRUG EXCRETION; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; KIDNEY INFARCTION; LIVER CELL CARCINOMA; MALIGNANT NEOPLASTIC DISEASE; NEPHROGENIC FIBROSING DERMOPATHY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHOTODYNAMIC THERAPY; PLASMA HALF LIFE; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; TUMOR LOCALIZATION; TUMOR NECROSIS;

EID: 45949097340     PISSN: 15734056     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340508784356789     Document Type: Review

References (148)

1. Ramani K, Judd RM, Holly TA, et al. Contrast magnetic resonance imaging in the assessment of myocardial viability in patients with stable coronary artery disease and left ventricular dysfunction. Circulation 1998; 98: 2687-94.
2. Kim FJ, Wu E, Rafael A, et al. The use of contrast-enhanced magnetic resonance imaging to identify reversible myocardial dysfunction. N Engl J Med 2000; 343: 1445-53.
3. Persira RS, Prato FS, Wisenberg G, Sykes J, Yvorchuk KJ. The use of Gd-DTPA as a marker of myocardial viability in reperfused acute myocardial infarction. Int J Cardiovasc Imag 2001; 17: 395-404.
4. Weinmann HJ, Ebert W, Misselwitz B, Schmitt-Willich H. Tissue-specific MR contrast agents. Eur J Radiol 2003; 46: 33-44.
5. Ni Y, Marchal G., Enhanced magnetic resonance imaging for tissue characterization of liver abnormalities with hepatobiliary contrast agents: An overview of preclinical animal experiments. Top Magn Reson Imag 1998; 9; 183-95.
6. Oshinski JN, Yang Z, Jones JR, et al. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with-magnetic resonance imaging. Circulation 2001; 104: 2838-42.
7. Saeed M, Lund G, Wendland MF, et al. Magnetic resonance characterization of the peri-infarction zone of reperfused myocardial infarction with necrosis-specific and extracellular nonspecific contrast media. Circulation 2001; 103: 871-76.
8. Choi CJ, Haji-Momenian S, Dimaria J, et al. Contrast washout by MRI identifies stunned myocardium in patients after reperfused myocardial infarction. J Cardiovasc Magn Reson 2002; 4: 19 (Abstract).
9. Ni Y, Pislaru C, Bosman H, et al. Intracoronary delivery of Gd-DTPA and Gadophrin-2 for determination of myocardial viability with MR imaging. Eur Radiol 2001; 11: 876-83.
10. Judd RM, Kim RJ, Oshinski, JN, et al. Imaging time after Gd-DTPA injection is critical in using delayed enhancement to determine infarct size accurately with magnetic resonance imaging (with response). Circulation 2002; 106: e6-6.
11. Jin JY, Teng GJ, Feng Y, et al. MR imaging of acute reperfused myocardial infarction: intraindividual comparison of ECIII-60 and Gd-DTPA in a swine model. CVIR 2007; 30: 248-56.
12. Vogel-Claussen J, Rochitte CE, Wu KC, et al. Delayed enhancement MR imaging: utility in myocardial assessment. Radiographics 2006; 26:795-810.
13. Bremer C, Bankert J, Filler T, Ebert W, Tombach B, Reimer P. High-dose Gd-DTPA vs. Bis-Gd-mesoporphyrin for monitoring laser-induced tissue necrosis. J Magn Reson Imaging 2005, 21, 801-08.
14. Ni Y, Bormans G, Chen F, Verbruggen A, and Marchal G. Necrosis avid contrast agents: Functional similarity versus structural diversity. Invest Radiol 2005; 40: 526-35.
15. Kessel D. Porphyrin localization: a new modality for detection and therapy of tumors, Biochem. Pharmacol 1994; 33: 1389-93.
16. Gomer C. Photodynamic therapy in the treatment of malignancies, Semin Hematol 1989; 26: 27-34.
17. Nelson J, Schmiedl U, Shankland E. Metalloporphyrins as tumor-seeking MRI contrast media and as potential selective treatment sensitizers. Invest Radiol 1990; 25: S71-3.
18. Pass H, Photodynamic therapy in oncology: mechanisms and clinical use (review). J Natl Cancer Inst 1993; 85: 443-56.
19. Lipson RL, Baldes EJ, Olsen AM. Hematoporphyrin derivative: A new aid for endoscopic detection of malignant disease. J Thorac Cardiovasc Surg 1961; 42:623-29.
20. Hahn SM, Fraker DL, Mick R, et al. A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis. Clin Cancer Res 2006; 12: 2517-25.
21. Brown SB, Brown EA, Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004; 5: 497-508.
22. Schaffer M, Schaffer PM, Corti L, et al. Photofrin as a specific radiosensitizing agent for tumors: studies in comparison to other porphyrins in an experimental in vivo model. J Photochem Photobiol B 2002; 66: 157-64.
23. Nelson JA, Schmiedl U. Porphyrins as contrast media. Magn Reson Med 1991; 22: 366-71.
24. Lam S, Palcic B, McLean D, Hung J, Korbelik M, Profio AE. Detection of early lung cancer using low dose Photofrin II. Chest 1990; 97: 333-7.
25. Nakajima S, Yamauchi H, Sakata I, et al. Indium-111-labeled manganese-metalloporphyrin for tumor imaging. Nucl Med Biol 1993; 20: 231-7.
26. Chen C, Cohen J, Myers C, and Sohn M. Paramagnetic metalloporphyrins as potential contrast agents in NMR imaging. FEBS Lett 1984; 168: 70-4.
27. Ogan M, Revel D, Brasch R. Metalloporphyrin contrast enhancement of tumors in magnetic resonance imaging: A study of human carcinoma, lymphoma, and fibrosarcoma in mice. Invest Radiol 1987; 22: 822-8.
28. Furmanski P, Longley C. Metalloporphyrin enhancement of magnetic resonance imaging of human tumor xenografts in nude mice. Cancer Res 1988; 48: 4604-10.
29. Van Zijl PCM, Place DA, Cohen JS, Faustino PJ, Lyon RC, Patronas NJ. Metalloporphyrin magnetic resonance contrast agents: Feasibility of tumor-specific magnetic resonance imaging. Acta Radiol suppl (Stockh) 1990; 374: 75-79.
30. Fiel RJ, Musser DA, Mark EH, Mazurchuk R, Alletto JJ. A comparative study of manganese meso-sulphonatophenyl porphyrins: Contrast enhancing agents for tumors. Magn Reson Imaging 1990; 8: 255-59.
31. Bockhorst K, Hohn-Berlage M, Kocher M, Hossmam KA. Proton relaxation enhancement in experimental brain tumors: in vivo NMR study of manganese (III) TPPS in rat brain gliomas. Magn Reson Imaging 1990; 8: 499-504.
32. Place DA, Faustino JP, Berghmans KK, van Ziji PCM, Chesnick AS, Cohen JS. MRI contrast-dose relationship of manganese (III) tetra (4-sulfonatophenyl) porphyrin with human xenograft tumors in nude mice at 2.0 T. Magn Reson Imaging 1992; 10: 919-28.
33. Ebert E, Hofmann S, Swiderski U, et al. Metallopophyrins: tumor-specific contrast agents? In: Rinck PA, Muller RN, editors. New Developments in Contrast Agent Research, Hamburg, Germany, European Magnetic Resonance Forum Foundation. 1992; 127-40.
34. Hindré F, LePlouzennec M, de Certained JD, Foultier MT, Patrice T, Simonneaux G. Tetra-p-amonophenylporphyrin conjugated with Gd-DTPA: tumor-specific contrast agent for MR imaging. JMRI 1993; 3: 59-65.
35. Young SW, Sidhu MK, Qing F, et al. Preclinical evaluation of Gadolinium (III) texaphyrin complex: A new paramagnetic contrast agent for magnetic resonance imaging. Invest Radiol 1994; 29: 330-38.
36. Saini SK, Jena A, Dey J, Sharma AK, Singh R. MnPcS4: A new MRI contrast enhancing agent for tumor localization in mice. Magn Reson Imaging 1995; 13: 985-90.
37. Maier FY, Ebert W, Lee-Vaupel M, Conrad J, Gries H. German patent application DE 43 05 523 A1, Feb. 17, 1993.
38. Barkhausen J, Ebert W, Debatin JF, Weinmann HJ. Imaging of myocardial infarction: comparison of magnevist and gadophrin-3 in rabbits. J Am Coll Cardiol 2002; 39: 1392-8.
39. Schalla S, Wendland ME, Higgins CB, Ebert W, Saeed M. Accentuation of high susceptibility of hypertrophied myocardium to ischemia: complementary assessment of Gadophrin-enhancement and left ventricular function with MRI. Magn Reson Med 2004; 51: 552-8.
40. Metz S, Daldrup-Link H, Richter T, et al. Detection and quantification of breast tumor necrosis with MR imaging: value of the necrosis-avid contrast agent Gadophrin-3. Acad Radiol 2003; 10: 484-90.
41. Young S W, Fan Q. Imaging of human colon cancer xenograft with gadolinium-texaphyrin. Invest Radiol 1996; 31: 280-3.
42. Young SW, Qing F, Harriman A, et al. Gadolinium(III) texaphyrin: A tumor selective radiation sensitizer that is detectable by MRI. Proc Natl Acad Sci USA 1996; 93: 6610-5.
43. Sessler JL, Miller RA. Texaphyrins: new drugs with diverse clinical applications in radiation and photodynamic therapy. Biochem Pharmacol 2000; 59: 733-9.
44. Ni Y, Marchal G, Van Damme B, et al. Magnetic resonance imaging, microangiography and histology in a rat model of primary liver cancer. Invest Radiol 1992; 27: 689-97.
45. Ni Y, Marchal G, Yu J, et al. Localization of metalloporphyrin induced "specific" enhancement in experimental liver tumors: comparison of magnetic resonance imaging, microangiographic and histologic findings. Acad Radiol 1995; 2: 687-99.
46. Ni Y, Petré C, Miao Y, et al. Magnetic resonance imaging-histomorphologic correlation studies on paramagnetic metalloporphyrins in rat models of necrosis. Invest Radiol 1997; 32: 770-9.
47. Ni Y, Marchal G, Herijgers P, et al. Paramagnetic metalloporphyrins: from enhancers for malignant tumors to markers of myocardial infarcts. Acad Radiol 1996; 3: S395-7.
48. Policard A. Etude sur les aspects offerts par des tumeurs experimentales examinées a la lumiere de Wood. C R Soc Biol 1924; 91: 1423-8.
49. Auler H, Banzer G. Untersuchungen über die Rolle der Porphyrine bei geschwulskranken Menschen und Tieren. Z krebsforsch 1942; 53: 65-8.
50. Hahn SM, Putt ME, Metz J, et al. Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy. Clin Cancer Res 2006; 12: 5464-70.
51. Yamamoto T, Matsumura A, Shibata Y, et al. Manganese-metalloporphyrin (ATN-10) as a tumor-localizing agent: magnetic resonance imaging and inductively coupled plasma atomic emission spectroscopy study with experimental brain tumors. Neurosurgery 1998; 42: 1332-7.
52. 14C] hematoporphyrin derivative distribution in malignant and normal tissue. Cancer Res 1979; 39: 146-51.
53. Dougherty J, Gomer CJ, Henderson BW, et al. Review: Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
54. Peng Q, Evensen JF, Rimington C, Moan JA. A comparison of different photosensitizing dyes with respect to uptake C3H-tumors and tissues of mice. Cancer Letter 1987; 36: 1-10.
55. Pan Q, Fu M, Zhao X. Photodynamic effect of hematoporphyrin on human cancer cells and normal diploid fibroblasts in vitro. Adv Exp Med Biol 1985; 193: 123-8.
56. Ni Y, Miao Y, Semmler W, Marchal G. Manganese-metalloporphyrin (ATN-10) as a tumor-localizing agent: magnetic resonance imaging and inductively coupled plasma atomic emission spectroscopy study with experimental brain tumors (letter-to-the editor). Neurosurgery 1999; 44: 1146-9.
57. Nasu H, Takehara Y, Isogai S, et al. Tumor enhancement using Mn-metalloporphyrin in mice: magnetic resonance imaging and histopathologic correlation. J Magn Reson Imaging 2004; 20: 294-9.
58. Evens AM, Balasubramanian L, Gordon LI. Motcxafin gadolinium induces oxidative stress and apoptosis in hematologic malignancies, Curr Treat Options Oncol 2005; 6: 289-96.
59. Viala J, Vanel D, Meingan P, Lartigau E, Carde P; Renschler M. Phases IB and 11 multidose trialof gadolinium texaphyrin, a radiation sensitizer detectable at MR imaging: preliminary results in brain metastases. Radiology 1999; 212: 755-9.
60. Bernhard EJ, Mitchell JB, Deen D, Cardel M, Rosenthal DI, Brown JM. Re-evaluating gadolinium(III)-texaphyrin as a radiosensitizing agent. Cancer Res 2000; 60: 86-91.
61. Bugelski PJ, Porter CW, Dougherty TJ. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res 1981; 41: 4606-12.
62. Holt S, Tulip J, Hamilton D, Cummins J, Fields A, Dick G. Experimental laser phototherapy of the morris 7777 hepatoma in the rat. Hepatology 1985; 5: 175-80.
63. Van Hillegersberg R, Van Den Berg JWO, Kett WJ, Terpstra OT, Wilson JHP. Selective accumulation of endogenously produced porphyrins in a liver metastasis model in rats. Gastroenterology 1992; 103: 647-51.
64. Chen B, Xu Y, Roskams T, et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer 2001; 93: 275-82.
65. Van de Putte M, Roskams T, Vandenheede JR, Agostinis P, de Witte PA. Elucidation of the tumoritropic principle of hypericin. Br J Cancer 2005; 92: 1406-13.
66. Chen F, Suzuki Y, Nagai N, et al. Visualizing stroke in rats with clinical imagers: A Feasibility Study. Radiology 2004; 233: 905-11.
67. Ni Y, Adzamli K, Miao Y, et al. MRI Contrast enhancement of necrosis by MP-2269 and Gadophrin-2 in a rat model of liver infarction. Invest Radiol 2001; 36: 97-103.
68. Ni Y, Huyghe D, Verbeke K, et al. First preclinical evaluation of mono-[123I]iodohypericin as a necrosis avid tracer agent. Eur J Nucl Med Mol Imaging 2006; 33: 595-601.
69. Flotats A, Carrió I. Non-invasive in vivo imaging of myocardial apoptosis and necrosis. Eur J Nucl Med Mol Imaging 2003; 30: 615-30.
70. Orlandi C, Crane PD, Edwards DS, et al. Early scintigraphic detection of experimental myocardial infarction in dogs with technetium-99m-glucaric acid. J Nucl-Med 1991; 32: 263-68.
71. Okada DR, Johnson III G, Liu ZL, Hocherman SD, Khaw BA, Okada RD. Early detection of infarct in reperfused canine myocardium using 99mTc-Glucarate. J Nucl Med 2004; 45: 655-64.
72. Adzamli IK, Blau M, Pfeffer MA, Davis MA. Phosphonate-modified Gd-DTPA complexes III: the detection of myocardial infarction by MRI. Magn Reson Med 1993; 29: 505-11.
73. 2+) pyrophosphate in ischemic and infarcted dog myocardium in early stages of acute coronary occlusion: histochemical and tissue-counting comparisons. J Nucl Med 1983; 24: 485-91.
74. Khaw BA, Strauss HW, Moore R, et al. Myocardial damage delineated by indium-111 antimyosin Fab and technetium-99m pyrophosphate. J Nucl Med 1987; 28: 76-82.
75. Weissleder R, Lee A, Khaw B, Shen T, Brady T. Antimyosin-labeled monocrystalline iron oxide allows detection of myocardial infarct: MR antibody imaging. Radiology 1992; 182: 381-5.
76. Ni Y. Myocardial viability. In: Bogaert J, Duerinckx AL, Rademakers FE (volume eds) Magnetic Resonance of the Heart and Great Vessels: Clinical Applications. 1st Ed, Berlin, Springer, 108, pp113-32.
77. Pislaru S, Ni Y, Pislaru C, et al. Noninvasive measurements of infarct size after thrombolysis with a necrosis-avid MRI contrast agent. Circulation 1999; 99: 690-6.
78. Dymarkowski S, Ni Y, Miao Y, et al. Value of T2-weightcd MRI early after myocardial infarction in dogs: comparison with bisgadolinium-mesoporphyrin enhanced- T1 -weighted MR and functional data from cine MRI. Invest Radiol 2002; 37: 77-85.
79. Ni Y, Cresens E, Adriaens P, et al. Necrosis avid contrast agents: introducing nonporphyrin species. Acad Radiol 2002; 9(suppl 1): S98-101.
80. Ni Y, Cresens E, Adriaens P, et al. Exploring multifunctional features of necrosis avid contrast agents. Acad Radiol 2002; 9(suppl 2): S488-90.
81. Ni Y, Dymarkowski S, Chen F, Bogaert J, Marchal G. Occlusive myocardial infarction: enhanced or not enhanced with necrosis avid contrast agents at magnetic resonance imaging. Radiology 2002; 225: 603-5.
82. Ni Y, Marchal G, Petrd C, et al. Metalloporphyrin enblinced magnetic resonance imaging of acute myocardial infarction (abstract). Circulation 1994; 90(Supplement): 1468.
83. Marchal G, Ni Y, Herijgers P, et al. Paramagnetic metalloporphyrins: infarct avid contrast agents for diagnosis of acute myocardial infarction by magnetic resonance imaging. Eur/Radiol 1996; 6: 1-8.
84. Herijgers P, Laycock SK, Ni Y, et al. Localization and determination of infarct size by Gd-mesoporphyrin enhanced MRI in dogs. Int J Cardiac Imaging 1997; 13: 499-507.
85. Marchal G, Ni Y. Use of porphyrin-complex or expanded porphyrin-complex as an infarction localization diagnosticum. US Patent 6,013,241, 2000
86. Ni Y, Pislaru C, Bosmans H, et al. Validation of intracoronary delivery of metalloporphyrin as an in vivo "histochemical staining" for myocardial infarction with MR imaging. Acad Radiol 1998; 5 (Suppl 1): S37-41.
87. Schneider G, Hayd C, Müller A, et al. Contrast enhanced MRI of experimentally induced brain infarctions in rabbits using Bis-Gd-MP as MR contrast agent. Proceedings of the Third Annual Scientific Meeting, Society of Magnetic Resonance, Nice, France, 1995, pp.1144.
88. Stillman AE, Wilke N, Jerosch-Herold M. Myocardial viability. Radiol Clin North Am 1999; 37: 361-78.
89. Saeed M, Bremerich J, Wendland M F, et al. Reperfused myocardial infarction as seen with use of necrosis-specific versus standard extracellular MR contrast media in rats. Radiology 1999; 213: 247-57.
90. Lim TH, Choi S II. MRI of myocardial infarction. JMRI 1999; 10: 686-93.
91. Wendland MF, Saced M, Lund G, Higgins CB. Contrast-enhanced MRI for quantification of myocardial viability. JMRI 1999; 10: 694-702.
92. Choi SI, Choi SH, Kim ST, et al. Irreversibly damaged myocardium at MR imaging with a necrotic tissue-specific contrast agent in a cat model. Radiology 2000; 215: 863-8.
93. Jeong AK, Choi SI, Kim DH, et al. Evaluation by contrast-enhanced MR imaging of the lateral border zone in reperfused myocardial infarction in a cat model. Korean J Radiol 2001; 2: 21-7.
94. Lund GK, Higgins CB, Wendland MF, Watzinger N, Weinmann HJ, Saced M. Assessment of Nicorandil therapy in ischemic myocardial injury by using contrast-enhanced and functional MR imaging. Radiology 2001; 221: 676-82.
95. Ni Y, Dymarkowski S. Chapter 2. Contrast agents for cardiac MRI, pp 33-50. In Clinical Cardiac MRI with Interactive CD-ROM, Boacrt J, Dymarkowski S and Taylor AM (Eds), Springer-Verlag, 2004.
96. Marnique A, Marie PY. The best of cardiac imaging 2002. Arch Mal Cocur Vaiss 2003; 96: 73-85.
97. Choi SH, Lee SS, Choi SII, et al. Occlusive myocardial infarction: investigation of bis-Gadolinium mesoporphyrins- enhanced T1-weighted MR imaging in a cat model. Radiology 2001; 220: 436-40.
98. Ni Y, Chen F, Dymarkowski S, Bogaert J, Marchal G. Proper bandling of research with invalid conclusion (Letter-to-Editor). Radiology 2003; 229: 608-10.
99. Ni Y, Miao Y, Bosmans H, et al. Evaluation of interventional liver tumor ablation with Gd-mesoporpbyfin enhanced magnetic resonance imaging (abs). Radiology 1997; 205(P): 319.
100. Ni Y, Miao Y, Bosmans, H, et al. Evaluation of interstitial liver tumor ablation with Gadophrin-2 enhanced MRI (abs). Eur Radiol 1999; 9(Suppl 1): 1220.
101. Schalla S, Higgins CB, Chujo M, Saeed M. Effect of potassium-channel opener therapy on reperfused infarction in hypertrophied hearts: demonstration of preconditioning by using functional and contrast-enhanced magnetic resonance imaging. J Cardiovasc Pharmacol Ther 2004; 9: 193-202.
102. Schalla S, Higgins CB, Saeed M. Long-term oral treatment with nicorandil prevents the progression of left ventricular hypertrophy and preserves viability. J Cardiovasc Pharmacol 2005; 45: 333-40.
103. Thomas D, Dumont C, Pickup S, et al. T1-weighted cine FLASH is superior to IR imaging of post-infarction myocardial viability at 4.7T. J Cardiovasc Magn Reson 2006; 8: 345-52.
104. Krombach GA. Higgins CB, Gunther RW, Kuhne T, Saeed M. MR contrast media for cardiovascular imaging [in German]. Röfo Fortschr Geb Röntgenstr Neuen Bildgeb Verfahr 2002; 174: 819-29.
105. Daldrup-Link HE, Rudelius M, Metz S, et al. Cell tracking with gadophrin-2: a bifunctional contrast agent for MR imaging, optical imaging, and fluorescence microscopy. Eur, J Nucl Med Mol Imaging 2004; 31: 1312-21.
106. Ni Y, Miao Y, Cresens E, et al. Paramagnetic metalloporphyrins: there exist necrosis-avid and non-avid species. Proceedings of 7th Annual Scientific Meeting for ISMRM 1999; 1: 346.
107. Marchal G, Verbruggen A, Ni Y. Adriaens P, Cresens E. Non-porphyrin compounds for use as a diagnosticum and/or pharmaceutical. International Patent Application PTC/BE99/00104.
108. Cresens E, Ni Y, Adriaens P, Verbruggen A, Marchal G. Substituted bis-indole derivatives useful as contrast agents, pharmaceutical compositions containing them and intermediates for producing them. International Patent Application PCT/BEO1/00192.
109. Jorgensen M. Quantitative determination of pamoic acid in dog and rat serum by automated ion-pair solid-phase extraction and reversed-phase high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998; 716: 315-23.
110. Shaaban M, Maskey RP, Wagner-Dobler I, Laatsch H. Pharacine, a natural p-cyclophane and other indole derivatives from Cytophaga sp. strain AM13.1. J Nat Prod 2002; 65: 1660-3.
111. Oberdorster E. Manufactured nanomaterials (fullerenes, C60) induce oxidative stress in the brain of juvenile largemouth bass. Environ Health Perspect 2004; 112: 1058-62.
112. Ni Y, Chen F, Mulier S, et al. Magnetic resonance imaging after radiofrequency ablation in a rodent model of liver tumor: tissue characterization using a novel necrosis avid contrast agent. Eur Radiol 2006; 16: 1031-40.
113. Saab-Ismail NH, Simor T, Gaszner B, Lorand T, Szollosy M, El-gavish GA. Synthesis and in vivo evaluation of new contrast agents for cardiac MRI. J Med Chem 1999; 42: 2852-61.
114. Suranyi P, Kiss P, Brott BC, et al. Percent infarct mapping: an R1-map-based CE-MRI method for determining myocardial viability distribution. Magn Reson Med 2006; 56: 535-45.
115. Botnar RM, Buecker A, Wiethoff AJ, et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 2004; 110: 1463-66.
116. Botnar RM, Perez AS, Witte S, et al. In vivo molecular imaging of acute and subacute thrombosis using a fibrin-binding magnetic resonance imaging contrast agent. Circulation 2004; 109: 2023-9.
117. Amirbekian S, Amirbekian V, Aguinaldo JS, et al. Molecular imaging of atherosclerosis-associated matrix metalloproteinases (MMPs) using a novel and specific MR imaging contrast agent-P947. Eur Radiol 2006; 16(Suppl 1): 258 (abs B-537).
118. Raatschen HJ, Swain R, Shames DM, et al. MRI tumor characterization using Gd-GlyMe-DOTA-perfluorooctyl-mannose-conjugate (Gadofluorine M), a protein-avid contrast agent. Contrast Media Mol Imaging 2006; 1: 113-20.
119. Jackson EF, Esparza-Coss E, Wen X, et al. Magnetic resonance imaging of therapy-induced necrosis using gadolinium-chelated polyglutamic acids. Int J Radiat Oncol Biol Phys 2007; 68(3): 830-8.
120. Ni Y, Mulier S, Miao Y, Michel L, Marchal G. A review of the general aspects of radiofrequency ablation. Abdom Imaging 2005; 30: 381-400.
121. Ni Y, Chen F, Marchal G. Differentiation of residual turner from benign periablational tissues after radiofrequency ablation: the role of MRI contrast agents. Radiology 2005; 237: 745-9.
122. Goldberg SN. Can we differentiate residual untreated tumor from tissue responses to heat following thermal tumor ablation? Radiology 2005; 234: 317-8.
123. Kim TJ, Moon WK, Cha JH, et al. VX2 carcinoma in rabbits after radiofrequency ablation: comparison of MR contrast agents for help in differentiating benign periablational enhancement from residual tumor. Radiology 2005; 234: 423-30.
124. Ni Y, Østensen J, Zhang H, et al. The potential role of necrosis avid contrast agents in therapeutic evaluation of radiofrequehcy tumor ablation: an experimental study in rat model of liver metastasis (abs). MAGMA 2002; 15(Suppl 1): 17.
125. Ni Y, Østensen J, Cresens E, Adriaens P, Verbruggen A, Marchal G. Multipurpose applications of necrosis avid contrast agent for MRI detection of liver metastasis and therapeutic evaluation of radiofrequency ablation: an experimental study in rats (abs). Radiology 2002; 225(P): 392.
126. Spokojny AM, Serur JR, Skillman J, Spears JR. Uptake of hematoporphyrin derivative by atheromatous plaques: studies in human in vitro and rabbit in vivo. J Am Coll Cardiol 1986; 8: 1387-92.
127. Vever-Bizet C, L'Epine Y, Delettre E, et al. Photofrin II uptake by atheroma in atherosclerotic rabbits, Fluorescence and high performance liquid chromatographic analysis on post-mortem aorta. Photochem Photobiol 1989; 49: 731-7.
128. Woodburn KW, Fan Q, Kessel D, et al. Phototherapy of cancer and atheromatous plaque with texaphyrins. J Clin Laser Med Surg 1996; 14: 343-8.
129. Taupitz M, Wagner S, Schnorr J, et al. Phase I clinical evaluation of citrate-coated monocrystalline very small superparamagnetic iron oxide particles as a new contrast medium or magnetic resonance imaging. Invest Radiol 2004; 39: 394-405
130. Schnorr J, Wagner S, Abramjuk C, et al. Comparison of the iron oxide-based blood-pool contrast medium VSOP-C184 with gadopentetate dimeglumine for first-pass magnetic resonance angiography of the aorta and renal arteries in pigs. Invest Radiol 2004; 39: 546-53.
131. Cavagna FM, Maggioni F, Castelli PM, et al. Gadolinium chelates with weak binding to serum proteins: a new class of high-efficiency, general purpose contrast agents for magnetic resonance imaging. Invest Radiol 1997; 32: 780-96.
132. Hofmann B, Bogdanov A, Marecos E, Ebert W, Semmler W, Weissleder R. Mechanism of Gadophrin-2 accumulation in tumor necrosis. JMRI 1999; 9: 36-41.
133. Parac-Vogt TN, Kimpe K, Laurent S, et al. Synthesis, characterization and pharmacokinetic evaluation of a potential MRI contrast agent containing two paramagnetic centra with albumin binding affinity. Chemistry 2005; 11: 3077-86.
134. Graff BA, Kvinnsland Y, Skretting A, Rofstad EK. Intratumour heterogeneity in the uptake of macromolecular therapeutic agents in human melanoma xenografts. Br J Cancer 2003; 88: 291-97.
135. Lauffer RB. Targeted relaxation enhancement agents for MRI. Magn Reson Med 1991; 22: 339-42.
136. Ni Y, Huyghe D, Chen F, Bormans G, Verbruggen A, Marchal G. Resume on necrosis avid contrast agents: furher expansion of scope. Acad Radiol 2005; 12 (suppl): 55-6.
137. Hamer PW, McGeachie JM, Davies MJ, Grounds MD. Evans blue dye as an in vivo marker of myofibre damage: optimising parameters for detecting initial myofibre membrane permeability. J Anat 2002; 290: 69-79.
138. Ni Y. Bormans G, Marchal G, Verbruggen A. Tissue infarction and necrosis specific compounds (of hypericin derivatives), Patent applicatior. PCT/ BE2004/000107.
139. Fonge HA, Burmans G. Ni Y, et al. Evaluation of mono-I-123-Hypersion as necrosis avid tracer agent. Eur J Nucl Med Mol I 2004;31(Suppl 2):S381.
140. Van de Putte M, Wang H, Chen F, de Witte P, Ni Y. Hypericin as a marker for determination of tissue viability after intratumoral ethanol injection in a murine liver tumor model. Acad Radiol 2008; 15(1):107-13.
141. Fonge H, Vanckx K, Wang H, et al. Noninvasive detection and quantification of acute myocardial infarction in rabbits using mono-[1231]odohypericin μSPECT. Eur Heart J 2008; 29: 260-9.
142. Van de Putte M, Wang H, Chen F, de Witte P, Ni Y. Hypericin as a marker for determination of tissue viability after radiofrequency ablation in a murine liver tumor model. Oncol Rep 2008; 19:927-32.
143. Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C. A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Meth 1995; 184: 39-51.
144. Higuehi M, Iwata N, Matsuba Y, Sato K, Sasamoto K, Saido TC. 19F and 1H MRI detection of amyloid beta plaques in vivo. Nat Neurosci 2005; 8: 527-33.
145. Li H, Fan X, Houghton J. Tumor microenviromnent: The role of the tumor stroma in cancer. J Cell Biochem 2007; 101: 805-15.
146. Parks WC, Wilson CL, López-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nature Rev Immunol 2004; 4: 617-29.
147. Demicova TN, Hamblin MR. Macrophage-targeted photodynamic therapy. Int J Immunopathol Pharmacol 2004; 17: 117-26.
148. Mikawa M, Kato H, Okumura M, et al. Paramagnetic water-soluble metallofullerenes having the highest relaxivity for MRI contrast agents. Bioconjug Chem 2001; 12: 510-4.